Literature DB >> 1737590

Prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with colorectal cancer.

N Tsavaris1, D Tsigalakis, A Bobota, E Tsoutsos, M Sarafidou, M Papazachariou, P Komitsopoulou, P Kosmidis.   

Abstract

In the present study, the serum immunoglobulin levels of 100 patients with colorectal cancer who had undergone antitumor therapy, were measured before and during therapy. We received three samples before therapy and further samples every 2 months after initiation of therapy. It was found that the group of patients having increased IgG (P less than 0.05) and perhaps IgM (P less than 0.1) levels showed a longer time to progression of disease and prolonged overall survival time. Based on this finding we conclude that survival can potentially be correlated with immunoglobulin levels. Studies with large numbers of patients, and orientated towards the correlation of immunoglobulin levels with specific clinical parameters may prove that immunoglobulins can play a prognostic role in survival for colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737590

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  Evaluation of serum immunoglobulin (IgG, IgM, IgA) in potentially malignant disorders of oral cavity - A case control study.

Authors:  Vivek M Tarsariya; Dhaval N Mehta; Nilesh Raval; Hiren H Patadiya; Kanan Vachhrajani; Albert Ashem
Journal:  J Oral Biol Craniofac Res       Date:  2020-09-08

2.  Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips.

Authors:  Veronika I Butvilovskaya; Sofya B Popletaeva; Vladimir R Chechetkin; Zhanna I Zubtsova; Marya V Tsybulskaya; Larisa O Samokhina; Leonid I Vinnitskii; Aligeydar A Ragimov; Elena I Pozharitskaya; Galina A Grigor Eva; Natalya Y Meshalkina; Svetlana V Golysheva; Nadezhda V Shilova; Nicolai V Bovin; Aleksander S Zasedatelev; Alla Y Rubina
Journal:  Cancer Med       Date:  2016-03-19       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.